Clinical Study
Prognostic Factors for Tumor Recurrence after a 12-Year, Single-Center Experience of Liver Transplantations in Patients with Hepatocellular Carcinoma
Table 1
Demographic, clinical, and pathological parameters of 283 patients with HCC receiving OLT at the Bologna Center between 1997 and 2009.
| Variables | |
| Gender | | Male | 241 (85%) | Female | 42 (15%) | Median age (years) | 57 (33–68) |
| Viral infection | | HCV-positive | 152 (54%) | HBV-positive | 70 (25%) | HCV, HBV-positive | 13 (5%) | HCV, HBV-negative | 48 (17%) | Median real MELD score | 15 (6–45) |
| Preoperative treatments | 222 (78%) | TACE | 158 (56%) | PEI | 30 (10%) | RF | 63 (22%) | Liver resection | 16 (6%) |
| Median AFP level at OLT (ng/mL) | 9 (1–6826) | Median preoperative tumor number | 2 (1–6) | Median preoperative tumor diameter (cm) | 2.5 (0.8–5) | Down-staging to MC | 39 (14%) | Fulfilling MC at OLT | 224 (79%) | Fulfilling up-to-7 criteria at OLT | 267 (94%) | Median tumor number at histology | 1 (0–12) | Median tumor diameter at histology (cm) | 2.5 (0–6) | Fulfilling MC at histology | 208 (73%) | Fulfilling up-to-7 criteria at histology | 249 (88%) |
| Tumor grading | | G0–G2 | 143 (50.5%) | G3–G4 | 140 (49.5%) |
| Microvascular invasion | 117 (41%) | Macrovascular invasion | 3 (1%) | Post-OLT M-TOR inhibitors | 43 (15%) |
|
|
HCC: hepatocellular carcinoma. OLT: orthotopic liver transplantation. HCV: hepatitis C virus. HBV: hepatitis B virus. MELD: Model for End-stage Liver Disease. TACE: trans-arterial chemoembolization. PEI: percutaneous alcohol injection. RF: radiofrequency ablation. AFP: alpha-fetoprotein. MC: Milan criteria.
|